Inklusionen i arm 3 blev stoppet som forud planlagt, da sikkerheden af Avastin med IFL- regimet var dokumenteret og blev anset for acceptabel.
Enrollment in Arm 3 was discontinued, as pre-specified, once safety of Avastin with the IFL regimen was established and considered acceptable.